This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Unmet Need Molecular Structure Guidelines Study design Efficacy Safety Dosing and Therapy Management Summary Important Safety Information Abbreviated Prescribing Information
  • LORBRENA™ demonstrated a significant improvement in PFS and superior intracranial response rates over crizotinib1*
  • LORBRENA™ is a treatment option for patients with ALK-positive advanced non-small-cell lung cancer who are treatment naïve or have been previously treated with at least one ALK tyrosine kinase inhibitor, including second-generation drugs, and who might have brain metastases2
  • LORBRENA™ showed 72% reduction in risk of progression or death vs. crizotinib5

*Study B7461006 (CROWN) - A total of 296 patients were randomized to LORBRENA™ (n=149) or crizotinib (n=147)1
B7461006 - The safety of LORBRENA™ was evaluated in 149 patients1

Abbreviations: ALK, Anaplastic lymphoma kinase; CNS, Central nervous system; CROWN, A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC: NSCLC, Non-small cell lung cancer; PFS, Progression-free survival; TKI, Tyrosine kinase inhibitor.

References:Lorbrena™ EDA leaflet approval date 26/4/2021.Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)‑7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H‑8,4(metheno)pyrazolo[4,3‑h][2,5,11]- benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–4744. Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133.Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. N Engl J Med. 2020;383(21):2018-2029

MOH Approval No: HF0098OA54/062022
Invalidation date: 12/06/2024

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


For Egypt Healthcare Professionals

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 If you select ""No"", you will be redirected to, the global Pfoizer websitee.
 I confirm that i am a healthcare professional resident in Egypt.

Yes No
You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.